Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Teniposide"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 233
Tytuł:
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
Autorzy:
Zhong K; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. .
Shi Y; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Gao Y; Department of Hematology, Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province), Shijiazhuang, China.
Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang Q; Department of Oncology, Shanxi Academy of Medical Sciences & Shanxi Bethune Hospital, Shanxi Bethune Hospital affiliated to Shanxi Medical University, Taiyuan, China.
Cen X; Department of Hematology, Peking University First Hospital, Beijing, China.
Xue M; Department of Hematology, Air Force Medical Center, Beijing, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhao Y; Department of Hematology, the General Hospital of PLA, Beijing, China.
Zhang L; Department of Lymphoma, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liang R; Department of Hematology, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
Wang N; Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.
Xie Y; Departments of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China.
Yang Y; Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China.
Liu A; Department of Hematology and Lymphoma, Cancer hospital of Harbin Medical University, Haerbin, China.
Bao H; Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.
Wang J; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Cao B; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Zhang W; Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Zhang W; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Aug 11; Vol. 23 (1), pp. 746. Date of Electronic Publication: 2023 Aug 11.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Central Nervous System Neoplasms*/pathology
Lymphoma*
Adult ; Humans ; Methotrexate/therapeutic use ; Teniposide/therapeutic use ; Induction Chemotherapy ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting Inhibition of Notch1 Signaling Pathway on the Study of Human Gastric Cancer Stem Cells with Chemosensitization.
Autorzy:
Dou Y; Clinical Laboratory, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China.
Wang J; Clinical Laboratory, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China.
Pokaż więcej
Źródło:
Computational intelligence and neuroscience [Comput Intell Neurosci] 2022 Apr 26; Vol. 2022, pp. 1098394. Date of Electronic Publication: 2022 Apr 26 (Print Publication: 2022).
Typ publikacji:
Journal Article; Retracted Publication
MeSH Terms:
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Stomach Neoplasms*/metabolism
Animals ; Carmustine/metabolism ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Mice, SCID ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Nestin/genetics ; Nestin/metabolism ; Receptor, Notch1/genetics ; Receptor, Notch1/metabolism ; Signal Transduction ; Teniposide/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Autorzy:
Rampotas A; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Oxford University Clinical Academic Graduate School, Oxford, UK.
Djebbari F; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Panitsas F; Department of Haematology, Laiko General Hospital, Athens, Greece.
Lees C; Royal Berkshire NHS Foundation Trust, Reading, UK.
Tsagkaraki I; Buckinghamshire Healthcare NHS Trust, Aylesbury, UK.
Gomes AR; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Prideaux S; Great Western Hospitals NHS Foundation Trust, Swindon, UK.
Chen L; Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK.
Prodger C; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Khera A; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Gray N; Wexham Park Hospital, Slough, UK.
Ellis L; Frimley Health NHS Foundation Trust, Frimley, UK.
Sangha G; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Lim WY; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Eyre TA; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Moore S; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Kothari J; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2021 Apr; Vol. 106 (4), pp. 563-573. Date of Electronic Publication: 2021 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Multiple Myeloma/*epidemiology
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clinical Decision-Making ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Disease Management ; Female ; Health Care Surveys ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Prognosis ; Teniposide/adverse effects ; Teniposide/therapeutic use ; Treatment Outcome ; United Kingdom/epidemiology
SCR Protocol:
VCD protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).
Autorzy:
Salvi F; Division of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy.
Luminari S; Hematology Unit, Azienda Unità Sanitaria Locale IRCCS, Reggio Emilia, Italy.; Surgical, Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Tucci A; Division of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Massidda S; Hematology and Transplant Center, Ospedale Oncologico di Riferimento Regionale Armando Businco, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Liberati AM; Oncohematology and autotransplantation Unit, Azienda Ospedaliera Santa Maria, Terni, Italy.
Stelitano C; Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
Zanni M; Division of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy.
Re A; Division of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Centurioni R; Internal medicine and hematology Unit, Azienda Sanitaria Unica Regionale Marche AV3, Civitanova Marche, Italy.
Freilone R; Department's Structure of Hematology, Ivrea, Italy.
Musuraca G; Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Nassi L; Division of Hematology Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità, Novara, Italy.
Patti C; Department of Hematology I, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Arcari A; Hematology Unit and Transplantion Center, 'Guglielmo da Saliceto' Hospital, Piacenza, Italy.
Tani M; Hematology, S. Maria delle Croci Hospital, Ravenna, Italy.
Pulsoni A; Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I 'Sapienza' University of Rome, Roma, Italy.
Pavone V; Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy.
Volpetti S; Department of Haematology, DISM Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Italy.
Peli A; Division of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Evangelista A; Clinical and Evaluative Epidemiology Unit, AOU Città della Salute e della Scienza di Torino e CPO Piemonte, Torino, Italy.
Spina M; Division of Medical Oncology and Immunorelated Tumors, National Cancer Institute, Aviano, Italy.
Ladetto M; Division of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy.
Merli F; Hematology Unit, Azienda Unità Sanitaria Locale IRCCS, Reggio Emilia, Italy.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (12), pp. 2890-2898. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Heart Diseases/*complications
Hodgkin Disease/*complications
Hodgkin Disease/*drug therapy
Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cardiotoxicity/etiology ; Carmustine/adverse effects ; Carmustine/therapeutic use ; Combined Modality Therapy ; Female ; Heart Diseases/diagnosis ; Hodgkin Disease/diagnosis ; Hodgkin Disease/mortality ; Humans ; Male ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Methylprednisolone/adverse effects ; Methylprednisolone/therapeutic use ; Neoplasm Staging ; Prognosis ; Recurrence ; Remission Induction ; Survival Analysis ; Teniposide/adverse effects ; Teniposide/therapeutic use ; Treatment Outcome
SCR Protocol:
MBVP protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Autorzy:
Uttervall K; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Borg Bruchfeld J; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Gran C; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Wålinder G; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Månsson R; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.; Department of Laboratory Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
Lund J; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Gahrton G; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Alici E; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Nahi H; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2019 Sep; Vol. 103 (3), pp. 247-254. Date of Electronic Publication: 2019 Jul 07.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Female ; Humans ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Teniposide/adverse effects ; Teniposide/therapeutic use ; Treatment Outcome
SCR Protocol:
VCD protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Toxic effects of VCD on kidneys and liver tissues: a histopathological and biochemical study.
Autorzy:
Ahmadian S; Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Biology, Faculty of Science, Azarbaijan Shahid Madani University, Tabriz, Iran.
Sheshpari S; Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Shariati St., Tabriz, Iran.
Mahdipour M; Stem Cell Research Center, Tabriz University of Medical Sciences, Daneshgah St., Tabriz, Iran. .; Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Daneshgah St., Tabriz, Iran. .
Pazhang M; Department of Biology, Faculty of Science, Azarbaijan Shahid Madani University, Tabriz, Iran.
Tsai PJ; Center for Developmental Biology and Regenerative Medicine Research, National Taiwan University/NTU, Taipei, Taiwan.; Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University/NTU, Taipei, Taiwan.
Nouri M; Stem Cell Research Center, Tabriz University of Medical Sciences, Daneshgah St., Tabriz, Iran.; Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Daneshgah St., Tabriz, Iran.
Rahbarghazi R; Stem Cell Research Center, Tabriz University of Medical Sciences, Daneshgah St., Tabriz, Iran.; Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Shahnazi M; Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Shariati St., Tabriz, Iran. .
Pokaż więcej
Źródło:
BMC research notes [BMC Res Notes] 2019 Jul 22; Vol. 12 (1), pp. 446. Date of Electronic Publication: 2019 Jul 22.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Kidney/*drug effects
Liver/*drug effects
Ovary/*drug effects
Alanine Transaminase/blood ; Animals ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Aspartate Aminotransferases/blood ; Creatinine/blood ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/toxicity ; Dexamethasone/administration & dosage ; Dexamethasone/toxicity ; Female ; Injections, Intraperitoneal ; Kidney/pathology ; Liver/pathology ; Ovary/pathology ; Primary Ovarian Insufficiency/chemically induced ; Primary Ovarian Insufficiency/diagnosis ; Random Allocation ; Rats, Wistar ; Teniposide/administration & dosage ; Teniposide/toxicity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.
Autorzy:
Yusenko M; Institute for Biochemistry, Westfälische-Wilhelms-Universität, D-48149, Münster, Germany.
Jakobs A; Institute for Biochemistry, Westfälische-Wilhelms-Universität, D-48149, Münster, Germany.
Klempnauer KH; Institute for Biochemistry, Westfälische-Wilhelms-Universität, D-48149, Münster, Germany. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2018 Sep 03; Vol. 8 (1), pp. 13159. Date of Electronic Publication: 2018 Sep 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Regulation, Leukemic*
Antineoplastic Agents, Phytogenic/*pharmacology
Etoposide/*pharmacology
Podophyllotoxin/*pharmacology
Proto-Oncogene Proteins c-myb/*antagonists & inhibitors
Teniposide/*pharmacology
Cell Line, Tumor ; DNA Damage ; Dose-Response Relationship, Drug ; High-Throughput Screening Assays ; Humans ; Leukocytes/drug effects ; Leukocytes/metabolism ; Leukocytes/pathology ; Proto-Oncogene Proteins c-myb/genetics ; Proto-Oncogene Proteins c-myb/metabolism ; Signal Transduction ; Small Molecule Libraries/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Chemical stability of teniposide in aqueous and parenteral lipid emulsions.
Autorzy:
Wang J; Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, PR China.
Cui Y
Tang X
Pokaż więcej
Źródło:
Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2009 Apr; Vol. 35 (4), pp. 508-13.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Phytogenic/*chemistry
Lipids/*chemistry
Teniposide/*chemistry
Antineoplastic Agents, Phytogenic/administration & dosage ; Chemistry, Pharmaceutical ; Chromatography, High Pressure Liquid ; Drug Compounding ; Drug Stability ; Drug Storage ; Emulsions ; Hydrogen-Ion Concentration ; Kinetics ; Solutions ; Technology, Pharmaceutical ; Temperature ; Teniposide/administration & dosage ; Water
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Autorzy:
Steidl E; Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.; Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pilatus U; Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
Hattingen E; Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
Steinbach JP; Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zanella F; Institute of Neuroradiology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
Ronellenfitsch MW; Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bähr O; Dr. Senckenberg Institute of Neurooncology, Center for Neurology and Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Dec 29; Vol. 11 (12), pp. e0168113. Date of Electronic Publication: 2016 Dec 29 (Print Publication: 2016).
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Bevacizumab/*therapeutic use
Biomarkers, Tumor/*metabolism
Glioblastoma/*drug therapy
Inositol/*metabolism
Magnetic Resonance Spectroscopy/*methods
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Female ; Glioblastoma/mortality ; Glioblastoma/pathology ; Humans ; Hydrogen/chemistry ; Lomustine/therapeutic use ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Prospective Studies ; Survival Analysis ; Teniposide/therapeutic use ; Tumor Microenvironment/drug effects ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/blood
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.
Autorzy:
Sun YC
Wang J
Guo CC
Sai K
Wang J
Chen FR
Yang QY
Chen YS
Wang J
To TS
Zhang ZP
Mu YG
Chen ZP; Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2014 Aug 25; Vol. 14, pp. 611. Date of Electronic Publication: 2014 Aug 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Tumor/*metabolism
Glioma/*drug therapy
MicroRNAs/*metabolism
Proto-Oncogene Proteins c-mdm2/*antagonists & inhibitors
Teniposide/*pharmacology
Biomarkers, Tumor/genetics ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic/drug effects ; Glioma/genetics ; Glioma/pathology ; Humans ; MicroRNAs/genetics ; Prognosis ; Proto-Oncogene Proteins c-mdm2/genetics ; Proto-Oncogene Proteins c-mdm2/metabolism ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Toward discovering new anti-cancer agents targeting topoisomerase IIα: a facile screening strategy adaptable to high throughput platform.
Autorzy:
Lin YS; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Huang WC; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Chen MS; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Hsieh TS; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan; Department of Biochemistry, Duke University Medical Center, Durham, North Carolina, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 May 08; Vol. 9 (5), pp. e97008. Date of Electronic Publication: 2014 May 08 (Print Publication: 2014).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
High-Throughput Screening Assays*
Antigens, Neoplasm/*metabolism
Antineoplastic Agents/*pharmacology
DNA Topoisomerases, Type II/*metabolism
DNA-Binding Proteins/*antagonists & inhibitors
DNA-Binding Proteins/*metabolism
Topoisomerase II Inhibitors/*pharmacology
Base Sequence ; DNA/chemistry ; DNA/genetics ; DNA/metabolism ; Drug Interactions ; Drug Screening Assays, Antitumor ; HCT116 Cells ; Humans ; Models, Molecular ; Molecular Targeted Therapy ; Nucleic Acid Conformation ; Perchlorates/pharmacology ; Sodium Compounds/pharmacology ; Teniposide/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Autorzy:
Sancho JM; Clinical Hematology Department, Institut Catalá d'Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Ribera JM
Xicoy B
Morgades M
Oriol A
Tormo M
del Potro E
Debén G
Abella E
Bethencourt C
Ortín X
Brunet S
Ortega-Rivas F
Novo A
López R
Hernández-Rivas JM
Sanz MA
Feliu E
Pokaż więcej
Corporate Authors:
PETHEMA Group
Źródło:
European journal of haematology [Eur J Haematol] 2007 Feb; Vol. 78 (2), pp. 102-10. Date of Electronic Publication: 2006 Nov 06.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Asparaginase/administration & dosage ; Asparaginase/adverse effects ; Comorbidity ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Daunorubicin/administration & dosage ; Daunorubicin/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Kaplan-Meier Estimate ; Male ; Mercaptopurine/administration & dosage ; Mercaptopurine/adverse effects ; Methotrexate/administration & dosage ; Methotrexate/adverse effects ; Middle Aged ; Neutropenia/chemically induced ; Neutropenia/prevention & control ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prognosis ; Remission Induction ; Severity of Illness Index ; Survival Analysis ; Teniposide/administration & dosage ; Teniposide/adverse effects ; Treatment Outcome ; Vincristine/administration & dosage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Autorzy:
Kadoyama K; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Kuwahara A
Yamamori M
Brown JB
Sakaeda T
Okuno Y
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2011 Oct 05; Vol. 30, pp. 93. Date of Electronic Publication: 2011 Oct 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adverse Drug Reaction Reporting Systems*
United States Food and Drug Administration*
Antineoplastic Agents/*adverse effects
Drug Hypersensitivity/*etiology
Asparaginase/adverse effects ; Bayes Theorem ; Data Mining ; Docetaxel ; Drug Hypersensitivity/drug therapy ; Etoposide/adverse effects ; Humans ; Paclitaxel/adverse effects ; Pharmacovigilance ; Procarbazine/adverse effects ; Prognosis ; Taxoids/adverse effects ; Teniposide/adverse effects ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Autorzy:
Qiao W; Department of Nuclear Medicine, The First People's Hospital, Shanghai Jiaotong University, China.
Zhao J
Wang C
Wang T
Xing Y
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2010 Feb; Vol. 15 (1), pp. 21-7.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*
Positron-Emission Tomography*
Tomography, X-Ray Computed*
Lymphoma, Non-Hodgkin/*surgery
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/administration & dosage ; Carmustine/administration & dosage ; Child ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Dexamethasone/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Non-Hodgkin/diagnostic imaging ; Lymphoma, Non-Hodgkin/drug therapy ; Male ; Melphalan/administration & dosage ; Middle Aged ; Predictive Value of Tests ; Prednisolone/administration & dosage ; Prednisone/administration & dosage ; Proportional Hazards Models ; Radiopharmaceuticals ; Rituximab ; Teniposide/administration & dosage ; Transplantation, Autologous ; Treatment Outcome ; Vincristine/administration & dosage ; Young Adult
SCR Protocol:
BEAM regimen; Dexa-BEAM protocol; VAP-cyclo protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Inhibition of DNA topoisomerase II in living cells stimulates illegitimate recombination.
Autorzy:
Umanskaya ON; Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova 34/5, Moscow, 119334 Russia.
Ioudinkova ES
Razin SV
Bystritskiy AA
Pokaż więcej
Źródło:
Doklady. Biochemistry and biophysics [Dokl Biochem Biophys] 2005 Nov-Dec; Vol. 405, pp. 423-5.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Recombination, Genetic*
Topoisomerase II Inhibitors*
Animals ; COS Cells ; Chlorocebus aethiops ; Enzyme Inhibitors/pharmacology ; Nucleic Acid Synthesis Inhibitors/pharmacology ; Teniposide/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.
Autorzy:
Vordermark D; Dept. of Radiation Oncology, University of Würzburg, Germany. vordermark_ />Kölbl O
Ruprecht K
Vince GH
Bratengeier K
Flentje M
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2005 May 30; Vol. 5, pp. 55. Date of Electronic Publication: 2005 May 30.
Typ publikacji:
Journal Article
MeSH Terms:
Dose Fractionation, Radiation*
Brain Neoplasms/*surgery
Glioma/*surgery
Radiosurgery/*methods
Radiotherapy/*methods
Antineoplastic Agents/pharmacology ; Brain Neoplasms/pathology ; Disease Progression ; Dose-Response Relationship, Radiation ; Glioblastoma/pathology ; Glioblastoma/surgery ; Glioma/pathology ; Humans ; Neoplasm Recurrence, Local ; Nimustine/pharmacology ; Prognosis ; Recurrence ; Stereotaxic Techniques ; Teniposide/pharmacology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Autorzy:
Simon GR; Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12002 Magnolia Drive, Tampa, FL 33612, USA.
Bunn PA Jr
Pokaż więcej
Źródło:
Cancer investigation [Cancer Invest] 2003; Vol. 21 (1), pp. 87-104.
Typ publikacji:
Comparative Study; Journal Article; Review
MeSH Terms:
Taxoids*
Antineoplastic Agents, Phytogenic/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Deoxycytidine/*analogs & derivatives
Lung Neoplasms/*drug therapy
Paclitaxel/*analogs & derivatives
Paclitaxel/*therapeutic use
Vinblastine/*analogs & derivatives
Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/radiotherapy ; Clinical Trials as Topic ; Combined Modality Therapy ; Deoxycytidine/administration & dosage ; Docetaxel ; Etoposide/administration & dosage ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Lung Neoplasms/radiotherapy ; Male ; Microtubules/drug effects ; Multicenter Studies as Topic ; Neoadjuvant Therapy ; Organoplatinum Compounds/administration & dosage ; Paclitaxel/administration & dosage ; Palliative Care ; Podophyllotoxin/administration & dosage ; Randomized Controlled Trials as Topic ; Salvage Therapy ; Survival Analysis ; Teniposide/administration & dosage ; Treatment Outcome ; Vinblastine/administration & dosage ; Vinorelbine ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 233

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies